文献速递血管炎

随机对照试验中巨细胞动脉炎的缓解定义是什么

What is a response in randomised controlled trials in giant cell arteritis?
PubMed 文献 · Ann Rheum Dis · 2023-02-17

糖皮质激素是巨细胞动脉炎(GCA)治疗的金标准,但仅用糖皮质激素的患者中高达85%出现不良事件,因此需要研究减少糖皮质激素用量的药物。既往随机对照试验采用了不同的主要终点,限制了荟萃分析中治疗效应的比较并造成不期望的结局异质性。本文讨论制定新的国际公认缓解标准的挑战与机遇。

要点

  • 既往GCA随机对照试验主要终点不同,限制了荟萃分析比较并造成结局异质性。
  • 疾病活动度变化是缓解的基本组成部分,但能否减少糖皮质激素及维持疾病状态是否纳入缓解评估仍有争议。
  • 影像学和新型实验室生物标志物作为疾病活动度客观标志物的作用需进一步研究。

核心结论

  • GCA研究中缓解评估的协调统一是重要的未满足需求。

研究设计与样本

  • 本文为观点文章,讨论制定新的国际公认缓解标准的挑战与机遇。

主要发现

  • 仅用糖皮质激素的患者中高达85%出现不良事件。
  • 既往随机对照试验采用了不同的主要终点,限制了荟萃分析中治疗效应的比较并造成不期望的结局异质性。
  • 疾病活动度变化是缓解的基本组成部分,但能否减少糖皮质激素及维持疾病状态是否应纳入缓解评估仍有争议。
  • 影像学和新型实验室生物标志物作为疾病活动度客观标志物的作用需进一步研究。
  • 未来缓解标准可能构建为多领域组合,但纳入哪些领域及其相对权重仍需回答。

局限性

  • 影像学和新型实验室生物标志物作为疾病活动度客观标志物的作用需进一步研究。
  • 未来缓解标准中纳入哪些领域及其相对权重仍需回答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucocorticoids (GCs) are the gold standard for treatment of giant cell arteritis (GCA); however, there is a need for studies on GC-sparing agents, given that up to 85% of patients receiving GC only develop adverse events. Previous randomised controlled trials (RCTs) have applied different primary endpoints, limiting the comparison of treatment effects in meta-analyses and creating an undesired heterogeneity of outcomes. The harmonisation of response assessment is therefore an important unmet need in GCA research. In this viewpoint article, we discuss the challenges and opportunities with the development of new, internationally accepted response criteria. A change of disease activity is a fundamental component of response; however, it is debatable whether the ability to taper GC and/or the maintenance of a disease state for a specific time period, as applied in recent RCTs, should be part of response assessment. The role of imaging and novel laboratory biomarkers as possible objective markers of disease activity needs further investigation but might be a possibility when drugs directly or indirectly influence the levels of traditional acute-phase reactants such as erythrocyte sedimentation rate and C reactive protein. Futures response criteria might be constructed as a multidomain set, but the questions about which domains will be included and what their relative weights will be still need to be answered.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Dejaco C, Ramiro S, Touma Z, et al. What is a response in randomised controlled trials in giant cell arteritis? Ann Rheum Dis. 2023. PMID: 36801812. doi:10.1136/ard-2022-223751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。